Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02190149 · ClinicalTrials.gov registry record
Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 64
- Enrollment target
NCT02190149: Completed study, sponsored by Baxalta now part of Shire.
NCT02190149 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02190149 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
Study Summary
This 6-month prospective outcomes study addresses the association between timing of infusion, patient activity levels, and bleeding episodes through patient-reported measurements.
Primary Outcome
After the informed consent form is signed, retrospective data on physical activity levels, infusion and occurrence of BEs will be collected. The retrospective period will be the 6 months prior to signing the ICF.
Interventions
- BIOLOGICAL ADVATE (Antihemophilic Factor [Recombinant])
- BIOLOGICAL RIXUBIS (Coagulation Factor IX [Recombinant])
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-07-22 |
| Est. Completion | 2016-03-29 |
What the finished NCT02190149 record still lists
NCT02190149 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which ADVATE (Antihemophilic Factor [Recombinant]) is the first listed.
NCT02190149 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02190149 about?
NCT02190149 is a clinical study titled "Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS". This 6-month prospective outcomes study addresses the association between timing of infusion, patient activity levels, and bleeding episodes through patient-reported measurements.
What is the current status of trial NCT02190149?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2014-07-22. Estimated completion is 2016-03-29.
What interventions are being tested in trial NCT02190149?
The interventions under investigation include: ADVATE (Antihemophilic Factor [Recombinant]) (BIOLOGICAL), RIXUBIS (Coagulation Factor IX [Recombinant]) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02190149?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI